Adoptive immunotherapy against sarcomas

Bibliography

• Gutierrez JC, Perez EA, Franceschi D, et al. Outcomes for soft-tissue sarcoma in 8249 cases from a large state cancer registry. J Surg Res 2007;141(1):105-14
   PubMed Web of Science ®Google Scholar
• Bacci G, Ferrari S, Bertoni F, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol 2000;18(24):4016-27
   PubMed Web of Science ®Google Scholar
• Heare T, Hensley MA, Dell’Orfano S. Bone tumors: osteosarcoma and Ewing’s sarcoma. Curr Opin Pediatr 2009;21(3):365-72
   PubMed Web of Science ®Google Scholar
• Hogendoorn PC, Athanasou N, Bielack S, et al. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 5):v204-13
   Google Scholar
• Casali PG, Blay JY; experts ECECPo. Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 5):v198-203
   PubMed Web of Science ®Google Scholar
• Casson AG, Putnam JB, Natarajan G, et al. Five-year survival after pulmonary metastasectomy for adult soft tissue sarcoma. Cancer 1992;69(3):662-8
   PubMed Web of Science ®Google Scholar
• Antonescu CR. The GIST paradigm: lessons for other kinase-driven cancers. J Pathol 2011;223(2):251-61
   PubMed Web of Science ®Google Scholar
• Fagioli F, Aglietta M, Tienghi A, et al. High-dose chemotherapy in the treatment of relapsed osteosarcoma: an Italian sarcoma group study. J Clin Oncol 2002;20(8):2150-6
   PubMed Web of Science ®Google Scholar
• Gelderblom H, Jinks RC, Sydes M, et al. Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials. Eur J Cancer 2011;47(6):895-902
   PubMed Web of Science ®Google Scholar
• Kempf-Bielack B, Bielack SS, Jürgens H, et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 2005;23(3):559-68
   PubMed Web of Science ®Google Scholar
• Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 2013;19(19):5300-9
   PubMed Web of Science ®Google Scholar
• Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012;24(2):207-12
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. Cell transfer immunotherapy for metastatic solid cancer–what clinicians need to know. Nat Rev Clin Oncol 2011;8(10):577-85
   PubMed Web of Science ®Google Scholar
• Curiel TJ. Historical perspectives and current trends in cancer immunotherapy. In: Eugenie Kleinerman. Cancer immunotherapy: paradigms, practice and promise. Eugenie Kleinerman Springer; New York, NY, USA: 2012
   Google Scholar
• Coley WB. II. Contribution to the Knowledge of Sarcoma. Ann Surg 1891;14(3):199-220
   PubMedGoogle Scholar
• Wiemann B, Starnes CO. Coley’s toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther 1994;64(3):529-64
   PubMed Web of Science ®Google Scholar
• American cancer society’s complete guide to complementary and alternative cancer therapiesmethods (2nd Ed). American Cancer Society; Atlanta, GA: 2009
   Google Scholar
• Dighe AS, Richards E, Old LJ, Schreiber RD. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1994;1(6):447-56
   PubMed Web of Science ®Google Scholar
• Kaplan DH, Shankaran V, Dighe AS, et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 1998;95(13):7556-61
   PubMed Web of Science ®Google Scholar
• Street SE, Cretney E, Smyth MJ. Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood 2001;97(1):192-7
   PubMed Web of Science ®Google Scholar
• Penn I. Malignant tumors in organ transplant recipients. Springer-Verlag; Berlin, Heidelberg, NY: 1970
   Google Scholar
• Boshoff C, Weiss R. AIDS-related malignancies. Nat Rev Cancer 2002;2(5):373-82
   PubMed Web of Science ®Google Scholar
• Gatti RA, Good RA. Occurrence of malignancy in immunodeficiency diseases. A literature review. Cancer 1971;28:89-98
   PubMed Web of Science ®Google Scholar
• Penn I. Sarcomas in organ allograft recipients. Transplantation 1995;60(12):1485-91
   PubMed Web of Science ®Google Scholar
• Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313(5795):1960-4
   PubMed Web of Science ®Google Scholar
• Swann JB, Vesely MD, Silva A, et al. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc Natl Acad Sci USA 2008;105(2):652-6
   PubMed Web of Science ®Google Scholar
• Bhardwaj N. Harnessing the immune system to treat cancer. J Clin Invest 2007;117(5):1130-6
   PubMed Web of Science ®Google Scholar
• Rusakiewicz S, Semeraro M, Sarabi M, et al. Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res 2013;73(12):3499-510
   PubMed Web of Science ®Google Scholar
• Berghuis D, Santos SJ, Baelde HJ, et al. Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression. J Pathol 2011;223(3):347-57
   PubMed Web of Science ®Google Scholar
• Brinkrolf P, Landmeier S, Altvater B, et al. A high proportion of bone marrow T cells with regulatory phenotype (CD4+CD25hiFoxP3+) in Ewing sarcoma patients is associated with metastatic disease. Int J Cancer 2009;125(4):879-86
   PubMed Web of Science ®Google Scholar
• Sorbye SW, Kilvaer TK, Valkov A, et al. Prognostic impact of peritumoral lymphocyte infiltration in soft tissue sarcomas. BMC Clin Pathol 2012;12:5
   PubMedGoogle Scholar
• Sorbye SW, Kilvaer T, Valkov A, et al. Prognostic impact of lymphocytes in soft tissue sarcomas. PLoS One 2011;6(1):e14611
   PubMed Web of Science ®Google Scholar
• Matsuo T, Shimose S, Kubo T, et al. Extraskeletal osteosarcoma with partial spontaneous regression. Anticancer Res 2009;29(12):5197-201
   PubMed Web of Science ®Google Scholar
• Crowe NY, Smyth MJ, Godfrey DI. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J Exp Med 2002;196(1):119-27
   PubMed Web of Science ®Google Scholar
• Shankaran V, Ikeda H, Bruce AT, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410(6832):1107-11
   PubMed Web of Science ®Google Scholar
• Tsukahara T, Kawaguchi S, Torigoe T, et al. Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5. Cancer Sci 2006;97(12):1374-80
   PubMed Web of Science ®Google Scholar
• Pollack SM, Loggers ET, Rodler ET, et al. Immune-based therapies for sarcoma. Sarcoma 2011;2011:438940
   PubMedGoogle Scholar
• Maki RG. Soft tissue sarcoma as a model disease to examine cancer immunotherapy. Curr Opin Oncol 2001;13(4):270-4
   PubMed Web of Science ®Google Scholar
• Ayyoub M, Taub RN, Keohan ML, et al. The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma. Cancer Immun 2004;4:7
   PubMedGoogle Scholar
• Jungbluth AA, Chen YT, Stockert E, et al. Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer 2001;92(6):856-60
   PubMed Web of Science ®Google Scholar
• Jungbluth AA, Antonescu CR, Busam KJ, et al. Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7. Int J Cancer 2001;94(2):252-6
   PubMed Web of Science ®Google Scholar
• Skubitz KM, Pambuccian S, Manivel JC, Skubitz AP. Identification of heterogeneity among soft tissue sarcomas by gene expression profiles from different tumors. J Transl Med 2008;6:23
   PubMedGoogle Scholar
• Pollack SM, Jungbluth AA, Hoch BL, et al. NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma. Cancer 2012;118(18):4564-70
   PubMed Web of Science ®Google Scholar
• Zou C, Shen J, Tang Q, et al. Cancer-testis antigens expressed in osteosarcoma identified by gene microarray correlate with a poor patient prognosis. Cancer 2012;118(7):1845-55
   PubMed Web of Science ®Google Scholar
• Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011;29(7):917-24
   PubMed Web of Science ®Google Scholar
• Leuci V, Mesiano G, Gammaitoni L, et al. Genetically redirected T lymphocytes for adoptive immunotherapy of solid tumors. Curr Gene 2014;14(1):52-62
   Google Scholar
• Circosta P, Granziero L, Follenzi A, et al. T cell receptor (TCR) gene transfer with lentiviral vectors allows efficient redirection of tumor specificity in naive and memory T cells without prior stimulation of endogenous TCR. Hum Gene Ther 2009;20(12):1576-88
   PubMed Web of Science ®Google Scholar
• Bendle GM LC, Hooijkaas AI, et al. Lethal graftversus-host disease in mouse models of T cell receptor gene therapy. Nat Med 2010;16(5):565-70
   PubMed Web of Science ®Google Scholar
• van Loenen MM, de Boer R, Amir AL, et al. Mixed T cell receptor dimers harbor potentially harmful neoreactivity. Proc Natl Acad Sci USA 2010;107(24):10972-7
   PubMed Web of Science ®Google Scholar
• Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011;3(95):95ra73
   PubMed Web of Science ®Google Scholar
• Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013;5(177):177ra38
   PubMed Web of Science ®Google Scholar
• Hombach A, Köhler H, Rappl G, Abken H. Human CD4+ T cells lyse target cells via granzyme/perforin upon circumvention of MHC class II restriction by an antibody-like immunoreceptor. J Immunol 2006;177(8):5668-75
   PubMed Web of Science ®Google Scholar
• Dotti G, Savoldo B, Brenner M. Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?". Hum Gene Ther 2009;20(11):1229-39
   PubMed Web of Science ®Google Scholar
• Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008;14(11):1264-70
   PubMed Web of Science ®Google Scholar
• Hombach AA, Heiders J, Foppe M, et al. OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells. Oncoimmunology 2012;1(4):458-66
   PubMed Web of Science ®Google Scholar
• Xu XJ, Tang YM. Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells. Cancer Lett 2014;343(2):172-8
   PubMed Web of Science ®Google Scholar
• Linette GP, Stadtmauer EA, Maus MV, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 2013;122(6):863-71
   PubMed Web of Science ®Google Scholar
• Louis CU, Savoldo B, Dotti G, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 2011;118(23):6050-6
   PubMed Web of Science ®Google Scholar
• Lamers CH, Willemsen R, van Elzakker P, et al. Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood 2011;117(1):72-82
   PubMed Web of Science ®Google Scholar
• Morgan RA, Yang JC, Kitano M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010;18(4):843-51
   PubMed Web of Science ®Google Scholar
• Kershaw MH, Westwood JA, Parker LL, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006;12(20 Pt 1):6106-15
   PubMed Web of Science ®Google Scholar
• Lamers CH, Langeveld SC, Groot-van Ruijven CM, et al. Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo. Cancer Immunol Immunother 2007;56(12):1875-83
   PubMed Web of Science ®Google Scholar
• Hamilton WB, Helling F, Lloyd KO, Livingston PO. Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography. Int J Cancer 1993;53(4):566-73
   PubMed Web of Science ®Google Scholar
• Zhang S, Zhang HS, Cordon-Cardo C, et al. Selection of tumor antigens as targets for immune attack using immunohistochemistry: protein antigens. Clin Cancer Res 1998;4(11):2669-76
   PubMed Web of Science ®Google Scholar
• Gottlieb DJ, Li YC, Lionello I, et al. Generation of tumour-specific cytotoxic T-cell clones from histocompatibility leucocyte antigen-identical siblings of patients with melanoma. Br J Cancer 2006;95(2):181-8
   PubMed Web of Science ®Google Scholar
• Topalian SL, Muul LM, Solomon D, Rosenberg SA. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods 1987;102(1):127-41
   PubMed Web of Science ®Google Scholar
• Balch CM, Riley LB, Bae YJ, et al. Patterns of human tumor-infiltrating lymphocytes in 120 human cancers. Arch Surg 1990;125(2):200-5
   PubMed Web of Science ®Google Scholar
• Théoleyre S, Mori K, Cherrier B, et al. Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcoma. BMC Cancer 2005;5:123
   PubMed Web of Science ®Google Scholar
• Pollack SM, Jones RL, Farrar EA, et al. Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells. J Immunother Cancer 2014;2(1):36
   PubMedGoogle Scholar
• Mackall CL, Rhee EH, Read EJ, et al. A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clin Cancer Res 2008;14(15):4850-8
   PubMed Web of Science ®Google Scholar
• Gattinoni L, Finkelstein SE, Klebanoff CA, et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 2005;202(7):907-12
   PubMed Web of Science ®Google Scholar
• Wang LX, Kjaergaard J, Cohen PA, et al. Memory T cells originate from adoptively transferred effectors and reconstituting host cells after sequential lymphodepletion and adoptive immunotherapy. J Immunol 2004;172(6):3462-8
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011;17(13):4550-7
   PubMed Web of Science ®Google Scholar
• Muranski P, Boni A, Wrzesinski C, et al. Increased intensity lymphodepletion and adoptive immunotherapy–how far can we go? Nat Clin Pract Oncol 2006;3(12):668-81
   PubMedGoogle Scholar
• Deichman GI, Kashkina LM, Kluchareva TE, et al. Inhibition of experimental and spontaneous lung metastases of highly metastatic Syrian hamster sarcoma cells by non-activated bone marrow and peritoneal exudate cells. Int J Cancer 1983;31(5):609-15
   PubMed Web of Science ®Google Scholar
• Moscovitch M, Slavin S. Anti-tumor effects of allogeneic bone marrow transplantation in (NZB X NZW)F1 hybrids with spontaneous lymphosarcoma. J Immunol 1984;132(2):997-1000
   PubMed Web of Science ®Google Scholar
• Castagna L, Sarina B, Todisco E, et al. Lack of activity of allogeneic stem cell transplantation with reduced-intensity conditioning regimens in advanced sarcomas. Bone Marrow Transplant 2005;35(4):421-2
   PubMed Web of Science ®Google Scholar
• Misawa A, Hosoi H, Tsuchiya K, et al. Regression of refractory rhabdomyosarcoma after allogeneic stem-cell transplantation. Pediatr Hematol Oncol 2003;20(2):151-5
   PubMed Web of Science ®Google Scholar
• Secondino S, Carrabba MG, Pedrazzoli P, et al. Reduced intensity stem cell transplantation for advanced soft tissue sarcomas in adults: a retrospective analysis of the European Group for Blood and Marrow Transplantation. Haematologica 2007;92(3):418-20
   PubMed Web of Science ®Google Scholar
• Thiel U, Wawer A, Wolf P, et al. No improvement of survival with reduced- versus high-intensity conditioning for allogeneic stem cell transplants in Ewing tumor patients. Ann Oncol 2011;22(7):1614-21
   PubMed Web of Science ®Google Scholar
• Thiel U, Koscielniak E, Blaeschke F, et al. Allogeneic stem cell transplantation for patients with advanced rhabdomyosarcoma: a retrospective assessment. Br J Cancer 2013;109(10):2523-32
   PubMed Web of Science ®Google Scholar
• Demirer T, Barkholt L, Blaise D, et al. Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors. Nat Clin Pract Oncol 2008;5(5):256-67
   PubMedGoogle Scholar
• Carnevale-Schianca F, Cignetti A, Capaldi A, et al. Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T-cells directed to a tumor-associated antigen are generated in vivo during GVHD. Blood 2006;107(9):3795-803
   PubMed Web of Science ®Google Scholar
• Farag SS, Caligiuri MA. Human natural killer cell development and biology. Blood Rev 2006;20(3):123-37
   PubMed Web of Science ®Google Scholar
• Caligiuri MA. Human natural killer cells. Blood 2008;112(3):461-9
   PubMed Web of Science ®Google Scholar
• Moretta L, Moretta A. Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J 2004;23(2):255-9
   PubMed Web of Science ®Google Scholar
• Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 2008;9(5):495-502
   PubMed Web of Science ®Google Scholar
• Curti A, Ruggeri L, D’Addio A, et al. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood 2011;118(12):3273-9
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Mancusi A, Capanni M, et al. Exploitation of alloreactive NK cells in adoptive immunotherapy of cancer. Curr Opin Immunol 2005;17(2):211-17
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Capanni M, Mancusi A, et al. The impact of donor natural killer cell alloreactivity on allogeneic hematopoietic transplantation. Transpl Immunol 2005;14(3-4):203-6
   PubMed Web of Science ®Google Scholar
• Aversa F, Terenzi A, Tabilio A, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005;23(15):3447-54
   PubMed Web of Science ®Google Scholar
• Cho D, Shook DR, Shimasaki N, et al. Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res 2010;16(15):3901-9
   PubMed Web of Science ®Google Scholar
• Verhoeven DH, de Hooge AS, Mooiman EC, et al. NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. Mol Immunol 2008;45(15):3917-25
   PubMed Web of Science ®Google Scholar
• Alici E, Sutlu T, Björkstrand B, et al. Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. Blood 2008;111(6):3155-62
   PubMed Web of Science ®Google Scholar
• Sutlu T, Alici E. Natural killer cell-based immunotherapy in cancer: current insights and future prospects. J Intern Med 2009;266(2):154-81
   PubMed Web of Science ®Google Scholar
• Buddingh EP, Schilham MW, Ruslan SE, et al. Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells. Cancer Immunol Immunother 2011;60(4):575-86
   PubMed Web of Science ®Google Scholar
• Pahl JH, Ruslan SE, Buddingh EP, et al. Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma. Clin Cancer Res 2012;18(2):432-41
   PubMed Web of Science ®Google Scholar
• Constant P, Davodeau F, Peyrat MA, et al. Stimulation of human gamma delta T cells by nonpeptidic mycobacterial ligands. Science 1994;264(5156):267-70
   PubMed Web of Science ®Google Scholar
• Todaro M, D’Asaro M, Caccamo N, et al. Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes. J Immunol 2009;182(11):7287-96
   PubMed Web of Science ®Google Scholar
• Todaro M, Orlando V, Cicero G, et al. Chemotherapy sensitizes colon cancer initiating cells to Vγ9Vδ2 T cell-mediated cytotoxicity. PLoS One 2013;8(6):e65145
   PubMedGoogle Scholar
• Vermijlen D, Ellis P, Langford C, et al. Distinct cytokine-driven responses of activated blood gammadelta T cells: insights into unconventional T cell pleiotropy. J Immunol 2007;178(7):4304-14
   PubMed Web of Science ®Google Scholar
• Wesch D, Glatzel A, Kabelitz D. Differentiation of resting human peripheral blood gamma delta T cells toward Th1- or Th2-phenotype. Cell Immunol 2001;212(2):110-17
   PubMed Web of Science ®Google Scholar
• Caccamo N, La Mendola C, Orlando V, et al. Differentiation, phenotype, and function of interleukin-17-producing human Vγ9Vδ2 T cells. Blood 2011;118(1):129-38
   PubMed Web of Science ®Google Scholar
• Li Z. Potential of human γδ T cells for immunotherapy of osteosarcoma. Mol Biol Rep 2013;40(1):427-37
   PubMed Web of Science ®Google Scholar
• Kato Y, Tanaka Y, Miyagawa F, et al. Targeting of tumor cells for human gammadelta T cells by nonpeptide antigens. J Immunol 2001;167(9):5092-8
   PubMed Web of Science ®Google Scholar
• Muraro M, Mereuta OM, Carraro F, et al. Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells. Cell Immunol 2007;249(2):63-72
   PubMed Web of Science ®Google Scholar
• Li Z, Xu Q, Peng H, et al. IFN-γ enhances HOS and U2OS cell lines susceptibility to γδ T cell-mediated killing through the Fas/Fas ligand pathway. Int Immunopharmacol 2011;11(4):496-503
   PubMed Web of Science ®Google Scholar
• Li Z, Peng H, Xu Q, Ye Z. Sensitization of human osteosarcoma cells to Vγ9Vδ2 T-cell-mediated cytotoxicity by zoledronate. J Orthop Res 2012;30(5):824-30
   PubMed Web of Science ®Google Scholar
• Schmidt-Wolf IG, Negrin RS, Kiem HP, et al. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 1991;174(1):139-49
   PubMed Web of Science ®Google Scholar
• Schmidt-Wolf IG, Lefterova P, Mehta BA, et al. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol 1993;21(13):1673-9
   PubMed Web of Science ®Google Scholar
• Sangiolo D, Martinuzzi E, Todorovic M, et al. Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers. Int Immunol 2008;20(7):841-8
   PubMed Web of Science ®Google Scholar
• Lu PH, Negrin RS. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 1994;153(4):1687-96
   PubMed Web of Science ®Google Scholar
• Mesiano G, Todorovic M, Gammaitoni L, et al. Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. Expert Opin Biol Ther 2012;12(6):673-84
   PubMed Web of Science ®Google Scholar
• Jäkel CE, Schmidt-Wolf IG. An update on new adoptive immunotherapy strategies for solid tumors with cytokine-induced killer cells. Expert Opin Biol Ther 2014;14(7):905-16
   PubMed Web of Science ®Google Scholar
• Gammaitoni L, Giraudo L, Leuci V, et al. Effective activity of cytokine induced killer cells against autologous metastatic melanoma including cells with stemness features. Clin Cancer Res 2013;19(16):4347-58
   PubMed Web of Science ®Google Scholar
• Hongeng S, Petvises S, Worapongpaiboon S, et al. Generation of CD3+ CD56+ cytokine-induced killer cells and their in vitro cytotoxicity against pediatric cancer cells. Int J Hematol 2003;77(2):175-9
   PubMed Web of Science ®Google Scholar
• Sangiolo D, Mesiano G, Gammaitoni L, et al. Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas. Cancer Res 2014;74(1):119-29
   PubMed Web of Science ®Google Scholar
• Todorovic M, Mesiano G, Gammaitoni L, et al. Ex vivo allogeneic stimulation significantly improves expansion of cytokine-induced killer cells without increasing their alloreactivity across HLA barriers. J Immunother 2012;35(7):579-86
   PubMed Web of Science ®Google Scholar
• Kuci S, Rettinger E, Voss B, et al. Efficient lysis of rhabdomyosarcoma cells by cytokine-induced killer cells: implications for adoptive immunotherapy after allogeneic stem cell transplantation. Haematologica 2010;95(9):1579-86
   PubMed Web of Science ®Google Scholar
• Rettinger E, Meyer V, Kreyenberg H, et al. Cytotoxic capacity of IL-15-stimulated cytokine-induced killer cells against human acute Myeloid leukemia and rhabdomyosarcoma in humanized preclinical mouse models. Front Oncol 2012;2:32
   PubMedGoogle Scholar
• Introna M, Borleri G, Conti E, et al. Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Haematologica 2007;92(7):952-9
   PubMed Web of Science ®Google Scholar
• Olioso P, Giancola R, Di Riti M, et al. Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. Hematol Oncol 2009;27(3):130-9
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987;316(15):889-97
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Lotze MT, Yang JC, et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989;210(4):474-84; discussion 84-5
   PubMed Web of Science ®Google Scholar
• Berghuis D, Schilham MW, Vos HI, et al. Histone deacetylase inhibitors enhance expression of NKG2D ligands in Ewing sarcoma and sensitize for natural killer cell-mediated cytolysis. Clin Sarcoma Res 2012;2(1):8
   PubMedGoogle Scholar